Eko
The
FDA just granted clearance to a suite of algorithms that could help
healthcare providers in the US more accurately screen for heart
conditions during routine physical exams. The algorithms, developed by
Eko, can help detect both heart murmurs, indicative of valvular or
structural heart disease, and atrial fibrillation, or AFib, which can
lead to blood clots, strokes, heart failure and other complications.
According
to the company, the AI can identify heart murmurs with 87 percent
sensitivity and 87 percent specificity. In comparison, primary care
physicians unaided by AI had a 43 percent sensitivity and 69 percent
specificity, according to a study in
European Heart Journal.
When used with the Eko DUO stethoscope, the AI reportedly detected AFib
with 99 percent sensitivity and 97 percent specificity.
"Two
centuries after its invention, the stethoscope is still the front line
tool to detect cardiovascular disease," says Dr. Patrick McCarthy,
Executive Director of the Bluhm Cardiovascular Institute at Northwestern
Medicine and member of Eko's Scientific Advisory Board. "Eko's
development of artificial intelligence algorithms to help clinicians
better interpret sounds, identify arrhythmias and detect heart murmurs
during a physical exam is going to make a huge difference in our ability
to care for patients."
The AI is meant to be used with Eko's
digital stethoscopes, which are already on the market. This FDA
clearance gives the company the greenlight to deploy its murmur- and
AFib-detection algorithms. In December, the
FDA granted another Eko algorithm "breakthrough status,"
fast-tracking it for approval. That algorithm uses ECG data to identify
Left Ventricular Ejection Fraction (LVEF), a measure commonly used to
diagnose heart failure. If and when that algorithm is cleared, Eko's
digital stethoscopes will be able to use AI to screen for heart failure,
valve disease and AFib, and all of that will be possible during routine
physical exams.
No comments:
Post a Comment